LENZ Therapeutics opened lower at $4.10, compared with its previous close of $4.11. In the last trading session, the stock traded between $3.94 and $4.12. It showed a sideways intraday trend.
An investment of $100 made 3 years ago in LENZ Therapeutics is now worth
$ 25.19
Resulting in a loss of
$ 74.81 (74.81%)
Note: Past profits do not guarantee future returns.
Rating from 5 Analysts
Today's Change
$-0.03 (-0.71%)
Day High
$4.12
Day Low
$3.94
Day Open
$4.10
Prev Close
$4.11
Volume
6,64,635
1W Return
17.88%
1M Return
12.58%
3M Return
-21.67%
6M Return
-59.15%
1Y Return
-84.57%
Market Cap ($ Mn)
128
PE Ratio
-
PB Ratio
0.73
PEG Ratio
-
ROE
-38.00%
ROCE
-42.17%
EPS (TTM)
$-0.99
1 Week
17.88%
1 Month
12.58%
3 Months
-21.67%
6 Months
-59.15%
9 Months
-69.79%
Piper Sandler maintains Neutral on LENZ Therapeutics, cuts target to $5
Piper Sandler maintains Neutral rating on LENZ Therapeutics. Price target lowered from $7 to $5. Analyst Biren Amin issued the revised recommendation.
24 days agoPomerantz probes Lenz Therapeutics over securities fraud claims
Pomerantz LLP is investigating Lenz Therapeutics for potential securities fraud. Q2FY26 total revenue was $5.5 million, with $3.8 million from one-time licensing milestones. Organic sales for VIZZ eye drops remained flat at $1.73 million despite 9% volume growth. Bank of America downgraded the stock to Neutral and cut the price target to $7.00.
1mo agoPomerantz investigates LENZ Therapeutics over securities fraud claims
Pomerantz LLP is investigating LENZ Therapeutics for potential securities fraud. Q2 total revenue of $5.5 million included $3.8 million from one-time licensing milestones. Organic VIZZ sales remained flat at $1.73 million with only 9% volume growth. Bank of America downgraded the stock to Neutral and cut price target to $7.00.
1mo agoPomerantz investigates Lenz Therapeutics over Q2 revenue mix and downgrade
Pomerantz LLP investigates securities fraud claims regarding LenZ Therapeutics (NASDAQ: LENZ). Q2 2026 total revenue of $5.5 million included $3.8 million in one-time licensing milestones. Organic sales for VIZZ eye drops were flat at $1.73 million with only 9% volume growth QoQ. Bank of America downgraded stock to Neutral and cut price target from $31.00 to $7.00. Probe focuses on potential misrepresentation of commercial launch progress.
2mo agoPiper Sandler lowers LENZ Therapeutics price target to $7
Piper Sandler analyst Biren Amin cut the price target for LENZ Therapeutics (NASDAQ: LENZ) from $12 to $7 while maintaining a Neutral rating. The move indicates a lower valuation expectation without altering the firm's core investment thesis.
3mo agoLENZ Therapeutics Q2 revenue beats estimates 131% on VIZZ sales
LENZ Therapeutics delivered Q2 2026 revenue of $5.486 million, surpassing estimates by 131% on strong license income and initial VIZZ product sales. Despite a widened net loss of $31.9 million due to increased SG&A expenses, the company advanced its global commercialization with new partnerships in the UK, Australia, New Zealand, and Canada.
3mo ago| Stock | LTP | Change % | Market Cap | PE |
|---|---|---|---|---|
| $547.03 | -0.16% | $1,38,692.89M | 31.55 | |
| $61.05 | +0.38% | $1,31,510.31M | 14.39 | |
| $248.69 | -0.85% | $1,00,625.20M | - | |
| $959.41 | +4.73% | $97,505.80M | 19.64 | |
| $977.58 | +0.62% | $61,476.10M | 38.99 | |
| $419.98 | -0.95% | $46,108.31M | 65.60 | |
| $180.70 | -6.40% | $39,083.96M | - | |
| $53.87 | -0.37% | $33,618.11M | 26.24 | |
| $70.01 | +0.81% | $31,173.07M | 32.37 | |
| $41.85 | +1.60% | $30,322.88M | - | |
| $120.75 | +1.05% | $26,490.14M | - | |
| $122.27 | +1.64% | $24,922.54M | 15.85 |
An investment of $100 made 3 years ago in LENZ Therapeutics is now worth
$ 25.19
Resulting in a loss of
$ 74.81 (74.81%)
Note: Past profits do not guarantee future returns.
